ArticleJournal of ovarian research2026
Identification of two novel PATL2 variants and transcriptome sequencing reveals their role in oocyte maturation.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeOocyte maturation defect (OMD) is a rare cause of female infertility characterized by the persistent arrest of oocytes at immature stages. While biallelic PATL2 variants have been associated with OMD, the underlying molecular mechanisms remain unclear. This study aimed to identify novel PATL2 variants in OMD patients and investigate their functional consequences using a Patl2 knockout (KO) mouse model.
methodsWe recruited two unrelated OMD patients and performed whole-exome sequencing (WES), followed by sanger validation of candidate variants. A CRISPR/Cas9-generated Patl2 KO mouse model was established, and transcriptomic profiling of oocytes from wild-type (WT) and Patl2
resultsWe identified three PATL2 variants in the patients: a novel frameshift variant (c.99delA, p.Glu35fs), a novel synonymous variant (c.930G > A, p.K310K) confirmed by mini-gene assay to disrupt splicing and a recurrent splicing variant (c.223 - 14_223-2delCCCTCCTGTTCCA, p.R75Vfs*21). Sequence variant analysis classified these variants as pathogenic/likely pathogenic according to the ACMG/AMP guidelines. Transcriptome sequencing of Patl2
conclusionWe identified the first likely pathogenic synonymous PATL2 variant causing aberrant splicing and a novel frameshift variant in OMD, broadening the PATL2 mutational spectrum. These findings provide direct evidence for PATL2's critical role in female reproduction, where it regulates mRNA expression of proteins essential for oocyte meiotic progression and early embryonic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.